Abingdon, United Kingdom, 17 November 2023 – Emergex Vaccines Holding Limited (‘Emergex’), a clinical-stage biotechnology company addressing major global infectious diseases through the development of 100% synthetic T cell-priming immune set-point candidates, today announced that it has signed a contract with the UK Department of Health and Social Care for £1,798,109 to advance a CD8 […]
/wp-content/uploads/2018/01/logo.png00gatekeeper/wp-content/uploads/2018/01/logo.pnggatekeeper2023-11-17 12:00:202023-11-17 16:48:28Emergex Signs Contract of £1,79M with the UK Department of Health and Social Care’s UK Vaccine Network (“UKVN”) to Advance Its Novel Synthetic T Cell-Priming Set-Point Candidate Against Chikungunya Virus
– Emergex and VIC plan to collaborate to further develop and commercialise Emergex’s proprietary T cell-based vaccine candidates as designated in Saudi Arabia and the agreed Territory (including GCC Member States, other Middle Eastern territories and specified regions). – The Collaboration Agreement ultimately shall grant VIC first rights to distribute potential licensed products and to […]
/wp-content/uploads/2018/01/logo.png00gatekeeper/wp-content/uploads/2018/01/logo.pnggatekeeper2023-10-05 12:00:212023-10-05 14:04:58Emergex and Saudi Arabia’s Vaccine Industrial Company (VIC) have signed MoU to Advance First-of-its-Kind Infectious Disease Solutions
– First-in-human intradermal administration of CoronaTcP™ was generally well-tolerated – Evidence for generation of virus-specific effector and memory CD8+ T cells – Data reinforce findings from trial of DengueTcP, Emergex’s product candidate for Dengue, further supporting the company’s T cell-based approach to protection against RNA viruses ABINGDON, United Kingdom, 19 July 2023 – Emergex Vaccines […]
/wp-content/uploads/2018/01/logo.png00gatekeeper/wp-content/uploads/2018/01/logo.pnggatekeeper2023-07-19 13:00:082023-10-12 10:15:19Emergex Reports Promising Data from Completed Swiss Phase I Trial of CoronaTcP™, T Cell-Priming Immune Set-Point Candidate for Betacoronaviruses
Highly experienced international Board Leader joins Emergex as the company grows and progresses clinical development of its pipeline of T cell-priming immune set-point candidates Abingdon, Oxon, UK, 29 June 2023 – Emergex Vaccines Holding Limited (‘Emergex’), a clinical-stage biotechnology company addressing major global infectious diseases through the development of fully synthetic T cell-priming immune set-point candidates, […]
/wp-content/uploads/2018/01/logo.png00gatekeeper/wp-content/uploads/2018/01/logo.pnggatekeeper2023-06-29 13:00:482023-06-29 14:30:04Emergex Appoints Sir Michael Rake as Board Chairman
Emergex and Brazil’s IBMP to co-fund Phase II and Phase III studies of Emergex’s Dengue Fever and Betacoronavirus T cell-priming immune set-point therapeutic candidates in Brazil, with potential to expand to additional indications IBMP has made an equity investment in Emergex, contributing to the funding of Phase II clinical trials Abingdon, Oxon, UK, 20 June […]
/wp-content/uploads/2018/01/logo.png00gatekeeper/wp-content/uploads/2018/01/logo.pnggatekeeper2023-06-20 13:00:332023-06-21 13:32:56Emergex and Brazil’s IBMP Announce Clinical Development Collaboration for T Cell-Priming Immune Set-Point Candidates
naNO-DENGUE trial results demonstrate that DengueTcP is well-tolerated with no treatment-related serious adverse events Immunogenicity data shows peptide antigen-specific effector and memory CD8+ T cells were elicited Clinical proof-of-concept demonstration for Emergex’s therapeutic platform, supporting further development Abingdon, Oxon, UK, 6 June 2023 – Emergex Vaccines Holding Limited (‘Emergex’), a clinical-stage biotechnology company addressing major global […]
/wp-content/uploads/2018/01/logo.png00gatekeeper/wp-content/uploads/2018/01/logo.pnggatekeeper2023-06-06 13:00:552023-07-21 16:34:33Emergex Announces Positive Phase I Trial Data for DengueTcP™, Its Novel T Cell-Priming Immune Set-Point Candidate
Peptides specific to Chikungunya (CHIKV) virus expressed on surfaces of infected cells (collectively termed the viral “ligandome”) experimentally identified The peptides are derived from CHIKV viral proteins that are highly conserved across the Togaviridae viral family This demonstrates Emergex’s ability to respond rapidly to infectious disease threats using its highly adaptable plug-and-play technology Abingdon, Oxon, […]
/wp-content/uploads/2018/01/logo.png00gatekeeper/wp-content/uploads/2018/01/logo.pnggatekeeper2022-11-28 07:00:302022-11-28 15:59:45Emergex Generates Chikungunya Ligandome, a Milestone in the Development of its T cell Adaptive Vaccine
– Vaccine construct comprised predominantly of peptides from early “eclipse phase” antigens targeting infections before viral replication is complete – Peptide sequences of the vaccine construct are derived from variola (smallpox) virus and monkeypox virus antigens of the same viral family (Poxviridae) – Construct has been synthesised to preclinical grade at Emergex’s in-house manufacturing site. […]
/wp-content/uploads/2018/01/logo.png00gatekeeper/wp-content/uploads/2018/01/logo.pnggatekeeper2022-10-18 07:00:302022-10-18 10:08:22Emergex Confirms Synthesis of a CD8+ T cell Adaptive Vaccine for Smallpox and Monkeypox
Abingdon, Oxon, UK, 12 October 2022 – Emergex Vaccines Holding Limited (‘Emergex’, or the ‘Company’), a clinical stage biotechnology company addressing major global infectious diseases through the development of fully synthetic CD8+ T cell Adaptive Vaccines, announces that it has acquired the assets of Zosano Pharma Corporation (Fremont, CA). The assets acquired include intellectual property, license […]
/wp-content/uploads/2018/01/logo.png00gatekeeper/wp-content/uploads/2018/01/logo.pnggatekeeper2022-10-12 07:00:072022-10-11 17:19:39Emergex Acquires Intradermal and Patch Drug Delivery Technology with Its Manufacturing Equipment from Zosano Pharma
Emergex will manufacture the candidate universal influenza vaccine to cGMP standards for use in Phase I human trials Emergex’s universal influenza vaccine is a radically different approach to inducing influenza immunity by employing the use of a combination of: Highly conserved Class I peptides from non-structural proteins (NSP) representative of pandemic influenza A strains which […]
/wp-content/uploads/2018/01/logo.png00gatekeeper/wp-content/uploads/2018/01/logo.pnggatekeeper2022-07-28 07:00:122022-07-28 07:58:39Emergex Announces GMP Production of its CD8+ T cell Universal Influenza Vaccine
Abingdon, Oxon, UK, 1 July 2022 – Emergex Vaccines Holding Limited (‘Emergex’, or the ‘Company’), a clinical-stage biotechnology company addressing major global infectious diseases through the development of fully synthetic CD8+ T cell Adaptive Vaccines, today announced that it has signed heads of terms for a collaboration with the Molecular Biology Institute of Paraná (IBMP) […]
/wp-content/uploads/2018/01/logo.png00gatekeeper/wp-content/uploads/2018/01/logo.pnggatekeeper2022-07-01 07:00:062022-06-30 16:22:37Emergex Vaccines signs Heads of Terms for a Collaboration with Molecular Biology Institute of Paraná (IBMP) in Brazil
– Emergex’s COVID-19 and Dengue CD8+ T cell Adaptive vaccines are already in clinical trials Abingdon, Oxon, UK, 17th May 2022 – Emergex Vaccines Holding Limited (‘Emergex’, or the ‘Company’), a clinical stage biotechnology company addressing major global infectious diseases through the development of fully synthetic CD8+ T cell Adaptive Vaccines, today announced that its […]
– Both studies fully recruited, with data from the Dengue Fever study anticipated in the summer – Preclinical data for Emergex’s Coronavirus vaccine candidate suggests that it could provide heterologous immunity to viruses from the same family Abingdon, Oxon, UK, 18 April 2022 – Emergex Vaccines Holding Limited (‘Emergex’, or the ‘Company’), a clinical stage […]
/wp-content/uploads/2018/01/logo.png00gatekeeper/wp-content/uploads/2018/01/logo.pnggatekeeper2022-04-18 07:00:332022-04-14 16:07:58Emergex Provides an Update on First-in-Human Studies of Its Novel Dengue Fever and Coronavirus T cell Adaptive Vaccines
· Emergex’s CD8+ T cell Adaptive Vaccine platform will now be used to generate a tularemia vaccine candidate that provides a cytotoxic (killing of infected cells) CD8+ T cell response and offers a means for rapid development suitable for deployment as a medical countermeasure. · Emergex’s ongoing Phase I clinical trials on vaccine candidates for […]
/wp-content/uploads/2018/01/logo.png00gatekeeper/wp-content/uploads/2018/01/logo.pnggatekeeper2022-04-14 07:00:302022-04-22 10:59:22Emergex Advances Vaccine Candidate for Tularemia, Highlighting the Potential of T cell Priming Vaccines in National Preparedness Initiatives
Abingdon, Oxon, UK, 7 April 2022 – Emergex Vaccines Holding Limited (‘Emergex’, or the ‘Company’), a company addressing major global infectious disease threats through the development of fully synthetic CD8+ T-Cell Adaptive Vaccines, today announces that it has entered into an agreement with ATCC to progress preclinical development of its Yellow Fever booster vaccine program. […]
/wp-content/uploads/2018/01/logo.png00gatekeeper/wp-content/uploads/2018/01/logo.pnggatekeeper2022-04-07 07:00:542022-04-06 16:44:22Emergex Signs Agreement with ATCC to Advance Studies of its Yellow Fever Booster Vaccine Candidate
Abingdon, Oxon, UK, 22 February 2022 – Emergex Vaccines Holding Limited (‘Emergex’, or ‘the Company’), a company tackling major global infectious disease threats through the development of 100% synthetic Priming T cell Adaptive Vaccines, today announces that it has been awarded a £490,525 grant by the UK government’s Department of Health and Social Care (‘DHSC’) […]
https://emergexvaccines.com/wp-content/uploads/2018/01/Home_Technology.jpg400700gatekeeper/wp-content/uploads/2018/01/logo.pnggatekeeper2022-02-22 07:00:282022-02-22 08:27:28Emergex Awarded £490,525 UK Aid Grant by the Department of Health and Social Care to Advance Synthetic T cell Vaccine Candidate for Chikungunya Virus
Emergex confirms that the viral peptides in its COVID-19 vaccine candidate are present in the following sequenced variants, including B.1.1.7(Alpha, UK), B.1.1.28 (Gamma, Brazil) B.1.351 (Beta, South Africa), B.1.429 (South Carolina) B.1.617.2 (Delta, India), B.1.1.529 (Omicron, multiple countries) – meaning that no impact on the efficacy of the vaccine is anticipated Emergex’s COVID-19 vaccine uses […]
https://emergexvaccines.com/wp-content/uploads/2021/08/stop.jpg423800gatekeeper/wp-content/uploads/2018/01/logo.pnggatekeeper2021-12-01 16:31:522021-12-03 13:59:10Emergex confirms its next generation T-Cell Priming COVID-19 vaccine candidate has the potential to be effective against all currently sequenced viral mutations
Synthetic vaccine designed to prime T-Cells to rapidly remove viral-infected cells from the body after infection May offer broad immunity against SARS-CoV-1 and all SARS-CoV-2 variants and provide long-lasting immunity that does not require seasonal booster vaccines Abingdon, Oxon, UK, 15 November 2021 – Emergex Vaccines Holding Limited (‘Emergex’, or ‘the Company’), a company tackling […]
https://emergexvaccines.com/wp-content/uploads/2018/01/Tech_Lab.jpg360360gatekeeper/wp-content/uploads/2018/01/logo.pnggatekeeper2021-11-15 07:00:422021-12-03 14:55:43Emergex announces approval to initiate Phase I clinical trial of its next generation COVID-19 vaccine candidate
The response to COVID-19 – a success story in vaccine development The accelerated development of vaccines against COVID-19 and their deployment in mass vaccination programmes has been a major public health achievement. The landscape of vaccine development has undergone rapid change in the global response to the pandemic, with the utilization of novel platforms to […]
Abingdon, Oxon, UK, 11 November 2021 – Emergex Vaccines Holding Limited (‘Emergex’, or ‘the Company’), a company tackling major global infectious disease threats through the development of 100% synthetic T Cell priming vaccines was pleased to read an interesting Nature paper published online yesterday, highlighting the role of T-Cells in some COVID-19 patients, providing rapid […]
/wp-content/uploads/2018/01/logo.png00gatekeeper/wp-content/uploads/2018/01/logo.pnggatekeeper2021-11-11 16:27:502021-11-11 16:27:50Nature paper provides further evidence of the benefits of eliciting a T-Cell response for COVID-19
Can One Vaccine Provide Immune Protection Against Multiple Pathogens? The idea of one vaccine offering a wide range of protection against multiple pathogens or strains is an attractive concept – it would reduce the demands on healthcare systems to deliver vaccination programmes, provide improved uptake of vaccines and reduce the burden for patients who may […]
https://emergexvaccines.com/wp-content/uploads/2021/08/stop.jpg423800gatekeeper/wp-content/uploads/2018/01/logo.pnggatekeeper2021-07-27 20:28:062021-12-06 10:02:36Can One Vaccine Provide Immune Protection Against Multiple Pathogens?
T-cell priming vaccines offer the potential to provide faster, broader and longer lasting immunity to reduce serious illness associated with infectious diseases such as COVID-19. Here’s why… The human immune system has evolved over millennia and includes a multitude of different immune effector cells, antibodies and signalling molecules. As our knowledge of this complex system […]
https://emergexvaccines.com/wp-content/uploads/2021/08/virus.jpg436800gatekeeper/wp-content/uploads/2018/01/logo.pnggatekeeper2021-07-27 20:24:352021-12-06 10:01:46T-cell priming vaccines offer the potential to provide faster, broader and longer lasting immunity to reduce serious illness associated with infectious diseases such as COVID-19. Here’s why…
Swiss regulatory authorities, including the Swiss Agency for Therapeutic Products (Swissmedic) have granted approval for a Phase I clinical trial of Emergex’s Dengue vaccine candidate The Phase I clinical trial will evaluate the safety and look for markers of T-Cell immune response in healthy volunteers Abingdon, Oxon, UK, 30 June 2021 – Emergex Vaccines Holding […]
/wp-content/uploads/2018/01/logo.png00gatekeeper/wp-content/uploads/2018/01/logo.pnggatekeeper2021-06-30 07:00:202021-06-29 22:09:33Emergex Receives Regulatory Approval for a Phase I Clinical Trial in Dengue of a T-Cell Priming Vaccine
Abingdon, Oxon, UK, 17 June 2021 – Emergex Vaccines Holding Limited (‘Emergex’, or ‘the Company’), a company tackling major global infectious disease threats through the development of synthetic ‘set point’ vaccines which prime the T-Cell immune response, is pleased to announce that Dr. Anthony Sedgwick has been appointed to the Company’s Board as a Non-Executive […]
/wp-content/uploads/2018/01/logo.png00gatekeeper/wp-content/uploads/2018/01/logo.pnggatekeeper2021-06-17 07:00:292021-06-17 07:42:29Emergex Appoints Dr. Anthony Sedgwick as Non-Executive Director
Appointments of Mr Robin Cohen as Business Development Director and Ms Susi Osborne as Manufacturing Director Abingdon, Oxon, UK, 23 February 2021 – Emergex Vaccines Holding Limited (‘Emergex’, or ‘the Company’), a company tackling major global infectious disease threats through the development of synthetic ‘set point’ vaccines which prime the T-Cell immune response, today announces […]
Emergex Notes U.S. Government Reports Highlighting the Importance of T-Cell Immunity in Controlling Viral Infections U.S. federal appropriations reports encourage support for T-Cell vaccine approaches for pandemic influenza during the 2021 fiscal year Abingdon, Oxon, UK, 28 January 2021 – Emergex Vaccines Holding Limited (‘Emergex’, or ‘the Company’), a company tackling major global infectious disease […]
/wp-content/uploads/2018/01/logo.png00gatekeeper/wp-content/uploads/2018/01/logo.pnggatekeeper2021-01-28 07:00:072021-01-28 06:53:14Emergex Notes U.S. Government Reports Highlighting the Importance of T-Cell Immunity in Controlling Viral Infections
Bio-Manguinhos, is a world leader in vaccine development and manufacturing and one of the productive units of Fiocruz, one of the world’s most respected public health research institutions Abingdon, Oxon, UK, 5 January 2021 – Emergex Vaccines Holding Limited (‘Emergex’, or ‘the Company’), a company tackling major global infectious disease threats through the development […]
/wp-content/uploads/2018/01/logo.png00gatekeeper/wp-content/uploads/2018/01/logo.pnggatekeeper2021-01-05 07:00:262021-01-27 17:25:34Emergex Vaccines signs Collaboration Agreement with Brazil’s Bio-Manguinhos/Fiocruz for the Development of a COVID-19 Vaccine
Investor support further endorsement of vaccine development strategy Novel approach to vaccine development could address urgent global need for safe, effective vaccines that can be rapidly developed and deployed Abingdon, Oxon, UK, 18 November 2020 – Emergex Vaccines Holding Limited (‘Emergex’), a company tackling major global infectious disease threats through the development of synthetic ‘set […]
/wp-content/uploads/2018/01/logo.png00gatekeeper/wp-content/uploads/2018/01/logo.pnggatekeeper2020-11-18 14:08:132020-11-18 14:12:09Emergex Vaccines Raises US$11 million to Advance Pipeline of Synthetic T-Cell Vaccines for Infectious Diseases
First detailed, empirical analysis of Class 1 epitopes presented by SARS-Cov-2 infected cells which define the T-Cell repertoire necessary for cytotoxic T-Cell function MHC expression library provides an accurate basis for COVID-19 T-Cell vaccine and related diagnostics development Doylestown PA, USA and Abingdon, Oxon, UK, 15 September 2020– Emergex Vaccines Holding Limited (‘Emergex’), a company […]
/wp-content/uploads/2018/01/logo.png00gatekeeper/wp-content/uploads/2018/01/logo.pnggatekeeper2020-09-15 09:24:242020-09-15 09:26:04Emergex Vaccines and George Mason University Identify T-Cell Epitopes Presented by SARS-Cov-2 Infected Cells
Acquisition brings critical technical pre-clinical vaccine development capabilities in-house and establishes US based Emergex subsidiary Emergex uniquely develops novel 100% synthetic ‘set-point’ T cell priming vaccines to address some of the world’s most pathogenic infectious diseases Current COVID-19 pandemic and ongoing threat of pandemic flu demonstrate urgent global need for safe, effective vaccines which can […]
/wp-content/uploads/2018/01/logo.png00gatekeeper/wp-content/uploads/2018/01/logo.pnggatekeeper2020-09-01 07:00:502020-08-28 17:24:59Emergex Vaccines forms US subsidiary (Emergex USA) by acquisition of laboratories, technology and assets of US-based T cell specialist biotech ImmProNano
First identification of epitopes which shape CD8 T cell response to commercial live attenuated vaccine has implications across RNA virus vaccine development Vaccine primes immune system against T cell epitopes that would be minor or subdominant in a natural infection and are derived from internal proteins Abingdon, UK and Rio de Janeiro, Brazil, 19 August […]
/wp-content/uploads/2018/01/logo.png00gatekeeper/wp-content/uploads/2018/01/logo.pnggatekeeper2020-08-19 12:28:232020-08-19 12:48:37Emergex and Bio-Manguinhos/Fiocruz Elucidate T Cell Epitopes Produced by Commercial Yellow Fever Vaccine
Emergex Vaccines and George Mason University’s (Mason) National Center for Biodefense and Infectious Diseases (NCBID) enter into an agreement relating to the development of CD8+ priming RNA virus vaccines In particular, NCBID researchers will partner to provide additional expertise, resources, and vital samples to complement Emergex’s existing vaccine programs, including for SARS-CoV-2 Abingdon, UK, 22 […]
/wp-content/uploads/2018/01/logo.png00gatekeeper/wp-content/uploads/2018/01/logo.pnggatekeeper2020-04-22 12:52:282020-04-22 12:55:51Emergex Signs Agreement with George Mason University for Highly Pathogenic RNA Virus Studies
/wp-content/uploads/2018/01/logo.png00gatekeeper/wp-content/uploads/2018/01/logo.pnggatekeeper2020-04-20 09:58:322020-04-22 16:54:19Publication of Coronavirus White Papers
Emergex develops set-point vaccines to prevent some of the world’s most immediate and virulent diseases such as Zika, Dengue Fever, Ebola and pandemic Flu Vickers Venture Partners led the fundraising and Dr Finian Tan, Chairman of Vickers Venture Partners joins Emergex’s Board of Directors Capital supports pipeline developments, including progressing its first-in-man Flavivirus (Dengue) vaccine […]
/wp-content/uploads/2018/01/logo.png00gatekeeper/wp-content/uploads/2018/01/logo.pnggatekeeper2020-01-09 09:22:202020-01-17 11:22:20Emergex Raises More Than US$11 million in a Series A Round to Progress its Pipeline of Set-point Vaccines for Infectious Diseases
Emergex today announced it has successfully completed the first step in the development of a candidate vaccine for the Gram-negative intracellular coccobacillus, Francisella tularensis.
/wp-content/uploads/2018/01/logo.png00gatekeeper/wp-content/uploads/2018/01/logo.pnggatekeeper2019-12-12 10:28:432019-12-13 18:02:26Emergex Completes First Step in the Development of a Vaccine Candidate Against Intracellular Bacterium and Bioterrorist Agent Francisella Tularensis
/wp-content/uploads/2018/01/logo.png00gatekeeper/wp-content/uploads/2018/01/logo.pnggatekeeper2019-12-10 09:43:492019-12-13 10:40:08Emergex Successfully Completes Preclinical Testing of its Lead Set-Point Vaccine Candidate for Dengue Fever and Other Flaviviruses
Emergex today announced that it has signed an R&D agreement with the Institute of Molecular and Cell Biology (IMCB) in Singapore to develop a fully synthetic vaccine against human viruses that cause Hand, Foot and Mouth Disease (HFMD). Emergex and IMCB will collaborate closely to develop the new vaccine, combining their personnel, specialist knowledge and expertise.
/wp-content/uploads/2018/01/logo.png00gatekeeper/wp-content/uploads/2018/01/logo.pnggatekeeper2019-06-27 09:35:392019-12-10 09:42:15Emergex Signs an R&D Agreement with IMCB to Develop a Vaccine for the Emerging Threat of Hand, Foot & Mouth Disease
Emergex today announces the appointment of Athanasios Papadopoulos, MD, as Chief Medical Officer (CMO), effective 1st March 2019. Dr. Papadopoulos will report directly to Emergex’s CEO Professor Thomas Rademacher.
Emergex Vaccines Holding Limited (‘Emergex’), a biotechnology company pioneering a novel approach to the development of vaccines for infectious diseases, today announces that it has successfully secured a state-of-the-art-research and development (R&D) facility at Milton Park, Oxfordshire.
/wp-content/uploads/2018/01/logo.png00gatekeeper/wp-content/uploads/2018/01/logo.pnggatekeeper2019-02-18 09:34:272019-02-27 10:18:33Emergex Secures State-of-the-art R&D Facility and Hires a Chief Scientific Officer to Drive Development of its Vaccines
Emergex Vaccines Holding Limited (‘Emergex’), a biotechnology company pioneering a new approach to synthetic vaccine development in the field of infectious diseases, today announces the successful completion of preclinical toxicology testing on the gold nanoparticle carrier system that forms the fundamental basis for Emergex’s entire infectious disease vaccine platform.
/wp-content/uploads/2018/01/logo.png00gatekeeper/wp-content/uploads/2018/01/logo.pnggatekeeper2018-10-24 08:59:532019-02-27 10:18:52Emergex Demonstrates Excellent Safety Profile for Gold Nanoparticle Used in its Vaccine Platform
Emergex Vaccines Holding Limited (‘Emergex’), a biotechnology company pioneering a new approach to synthetic vaccine development in the field of infectious diseases, today announces that it has signed a Memorandum of Understanding (MoU) with Brazil-based Oswaldo Cruz Foundation ‘Fiocruz’ for the development of viral vaccines. The MoU initially covers the development of a vaccine that universally targets diseases within the flavivirus family such as Dengue Fever, Zika and Yellow Fever but could be expanded to include the development of vaccines to target other viral families that are endemic to the region.
/wp-content/uploads/2018/01/logo.png00gatekeeper/wp-content/uploads/2018/01/logo.pnggatekeeper2018-09-20 09:00:472019-02-27 10:19:11Emergex Enters into MoU with Brazil’s Fiocruz to Develop Novel Vaccines Against Viral Diseases
Emergex Vaccines Holding Limited (‘Emergex’), a biotechnology company pioneering a new approach to vaccine development in the field of infectious diseases, today announces that it has appointed The Conafay Group, US Federal Government experts, to advise on the US healthcare landscape and policy and to provide introductions to help establish new business contacts.
/wp-content/uploads/2018/01/logo.png00gatekeeper/wp-content/uploads/2018/01/logo.pnggatekeeper2018-07-13 09:37:592019-02-27 10:19:38Emergex Appoints US Federal Government Experts The Conafay Group
Emergex Vaccines Holding Limited (‘Emergex’), a biotechnology company pioneering a new approach to enable synthetic vaccine development in the field of infectious diseases, today announces that it has filed a patent in the USA for its novel pandemic flu vaccine.
/wp-content/uploads/2018/01/logo.png00gatekeeper/wp-content/uploads/2018/01/logo.pnggatekeeper2018-05-24 08:54:282020-01-17 11:23:54Emergex Files a Patent in the USA for its Novel Pandemic Flu Vaccine
Emergex Vaccines Holding Limited (‘Emergex’), a biotechnology company pioneering a new approach to vaccine development in the field of infectious diseases, today announces that Innovate UK, the UK’s innovation agency, has awarded the company a grant of £979,318 to progress its universal flu vaccine programme through preclinical development.
/wp-content/uploads/2018/01/logo.png00gatekeeper/wp-content/uploads/2018/01/logo.pnggatekeeper2018-05-14 09:11:082019-02-27 10:20:01Emergex Awarded Innovate UK Grant to Progress its Universal and Pandemic Flu Vaccine
Emergex Vaccines Holding Limited (‘Emergex’), a biotechnology company pioneering a new approach to vaccine development in the field of infectious diseases, today announces that Sir David King has joined Emergex’s Board as a Non-Executive Director.
/wp-content/uploads/2018/01/logo.png00gatekeeper/wp-content/uploads/2018/01/logo.pnggatekeeper2018-03-29 09:00:342019-02-27 10:20:18Sir David King Joins Emergex’s Board of Directors
Emergex Vaccines Holding Limited (‘Emergex’), a biotechnology company pioneering a new approach to vaccine development in the field of infectious diseases, today announces that it has built its Finance team and strengthening its operational capabilities.
/wp-content/uploads/2018/01/logo.png00gatekeeper/wp-content/uploads/2018/01/logo.pnggatekeeper2018-03-28 08:59:382019-02-27 10:21:05Emergex Builds its Finance Team with Two New Recruits
Emergex Vaccines Holding Limited (“Emergex”), a private biotechnology company pioneering a new approach to vaccine development in the field of infectious diseases, today provides an update on its vaccine development pipeline and business.
/wp-content/uploads/2018/01/logo.png00gatekeeper/wp-content/uploads/2018/01/logo.pnggatekeeper2018-03-26 09:15:352019-02-27 10:21:20Emergex Progresses its Synthetic Vaccine Development Pipeline
Emergex Vaccines Holding Limited (“Emergex”), a biotechnology company pioneering a new approach to T-cell vaccine development in the field of infectious diseases, today announced that they have been awarded a £499,825 SBRI contract with the Department of Health/Technology Strategy Board, facilitated by Innovate UK, the UK’s Innovation Agency. The ‘Vaccines for Global Development – Preclinical’ grant proceeds will be used to advance the Zika and multivalent filovirus (Ebola and Marburg) vaccine programmes.
/wp-content/uploads/2018/01/logo.png00gatekeeper/wp-content/uploads/2018/01/logo.pnggatekeeper2017-04-05 13:13:212020-01-17 11:24:36Emergex Vaccines Awarded SBRI Contract by Innovate UK
Emergex Vaccines Holding Limited (“Emergex”), a biotechnology company pioneering a new approach to T-cell vaccine development in the field of infectious diseases, today announces that they have been approved as a member of the Social Stock Exchange, society’s market for impact investing. This follows the ratification of Emergex’s impact report by the Social Stock Exchange’s independent Admissions Panel.
/wp-content/uploads/2018/01/logo.png00gatekeeper/wp-content/uploads/2018/01/logo.pnggatekeeper2017-02-20 13:14:242020-01-17 11:23:36Emergex Vaccines Approved as Member of the Social Stock Exchange
Emergex Vaccines Holding Limited (“Emergex”), a biotechnology company pioneering a new approach to T-cell vaccine development in the field of infectious diseases, today announced that it has paid an upfront technology access fee and option payment of £450,000 to Midatech Pharma (AIM: MTPH, NASDAQ: MTP), under the terms of the contract. This follows the licence granted to Emergex from Midatech Pharma, which was announced in January this year.
/wp-content/uploads/2018/01/logo.png00gatekeeper/wp-content/uploads/2018/01/logo.pnggatekeeper2016-11-22 13:02:272020-01-17 11:25:00Emergex Vaccines Provides an Update on Agreement with Midatech Pharma
Emergex Signs Contract of £1,79M with the UK Department of Health and Social Care’s UK Vaccine Network (“UKVN”) to Advance Its Novel Synthetic T Cell-Priming Set-Point Candidate Against Chikungunya Virus
Abingdon, United Kingdom, 17 November 2023 – Emergex Vaccines Holding Limited (‘Emergex’), a clinical-stage biotechnology company addressing major global infectious diseases through the development of 100% synthetic T cell-priming immune set-point candidates, today announced that it has signed a contract with the UK Department of Health and Social Care for £1,798,109 to advance a CD8 […]
Emergex and Saudi Arabia’s Vaccine Industrial Company (VIC) have signed MoU to Advance First-of-its-Kind Infectious Disease Solutions
– Emergex and VIC plan to collaborate to further develop and commercialise Emergex’s proprietary T cell-based vaccine candidates as designated in Saudi Arabia and the agreed Territory (including GCC Member States, other Middle Eastern territories and specified regions). – The Collaboration Agreement ultimately shall grant VIC first rights to distribute potential licensed products and to […]
Emergex Reports Promising Data from Completed Swiss Phase I Trial of CoronaTcP™, T Cell-Priming Immune Set-Point Candidate for Betacoronaviruses
– First-in-human intradermal administration of CoronaTcP™ was generally well-tolerated – Evidence for generation of virus-specific effector and memory CD8+ T cells – Data reinforce findings from trial of DengueTcP, Emergex’s product candidate for Dengue, further supporting the company’s T cell-based approach to protection against RNA viruses ABINGDON, United Kingdom, 19 July 2023 – Emergex Vaccines […]
Emergex Appoints Sir Michael Rake as Board Chairman
Highly experienced international Board Leader joins Emergex as the company grows and progresses clinical development of its pipeline of T cell-priming immune set-point candidates Abingdon, Oxon, UK, 29 June 2023 – Emergex Vaccines Holding Limited (‘Emergex’), a clinical-stage biotechnology company addressing major global infectious diseases through the development of fully synthetic T cell-priming immune set-point candidates, […]
Emergex and Brazil’s IBMP Announce Clinical Development Collaboration for T Cell-Priming Immune Set-Point Candidates
Emergex and Brazil’s IBMP to co-fund Phase II and Phase III studies of Emergex’s Dengue Fever and Betacoronavirus T cell-priming immune set-point therapeutic candidates in Brazil, with potential to expand to additional indications IBMP has made an equity investment in Emergex, contributing to the funding of Phase II clinical trials Abingdon, Oxon, UK, 20 June […]
Emergex Announces Positive Phase I Trial Data for DengueTcP™, Its Novel T Cell-Priming Immune Set-Point Candidate
naNO-DENGUE trial results demonstrate that DengueTcP is well-tolerated with no treatment-related serious adverse events Immunogenicity data shows peptide antigen-specific effector and memory CD8+ T cells were elicited Clinical proof-of-concept demonstration for Emergex’s therapeutic platform, supporting further development Abingdon, Oxon, UK, 6 June 2023 – Emergex Vaccines Holding Limited (‘Emergex’), a clinical-stage biotechnology company addressing major global […]
Emergex Generates Chikungunya Ligandome, a Milestone in the Development of its T cell Adaptive Vaccine
Peptides specific to Chikungunya (CHIKV) virus expressed on surfaces of infected cells (collectively termed the viral “ligandome”) experimentally identified The peptides are derived from CHIKV viral proteins that are highly conserved across the Togaviridae viral family This demonstrates Emergex’s ability to respond rapidly to infectious disease threats using its highly adaptable plug-and-play technology Abingdon, Oxon, […]
Emergex Confirms Synthesis of a CD8+ T cell Adaptive Vaccine for Smallpox and Monkeypox
– Vaccine construct comprised predominantly of peptides from early “eclipse phase” antigens targeting infections before viral replication is complete – Peptide sequences of the vaccine construct are derived from variola (smallpox) virus and monkeypox virus antigens of the same viral family (Poxviridae) – Construct has been synthesised to preclinical grade at Emergex’s in-house manufacturing site. […]
Emergex Acquires Intradermal and Patch Drug Delivery Technology with Its Manufacturing Equipment from Zosano Pharma
Abingdon, Oxon, UK, 12 October 2022 – Emergex Vaccines Holding Limited (‘Emergex’, or the ‘Company’), a clinical stage biotechnology company addressing major global infectious diseases through the development of fully synthetic CD8+ T cell Adaptive Vaccines, announces that it has acquired the assets of Zosano Pharma Corporation (Fremont, CA). The assets acquired include intellectual property, license […]
Emergex Announces GMP Production of its CD8+ T cell Universal Influenza Vaccine
Emergex will manufacture the candidate universal influenza vaccine to cGMP standards for use in Phase I human trials Emergex’s universal influenza vaccine is a radically different approach to inducing influenza immunity by employing the use of a combination of: Highly conserved Class I peptides from non-structural proteins (NSP) representative of pandemic influenza A strains which […]
Emergex Vaccines signs Heads of Terms for a Collaboration with Molecular Biology Institute of Paraná (IBMP) in Brazil
Abingdon, Oxon, UK, 1 July 2022 – Emergex Vaccines Holding Limited (‘Emergex’, or the ‘Company’), a clinical-stage biotechnology company addressing major global infectious diseases through the development of fully synthetic CD8+ T cell Adaptive Vaccines, today announced that it has signed heads of terms for a collaboration with the Molecular Biology Institute of Paraná (IBMP) […]
Emergex Vaccines Announces the Successful Coating of its Novel CD8+ T cell Adaptive COVID-19 Vaccine onto Zosano Pharma’s Micro-Needle Patch
– Emergex’s COVID-19 and Dengue CD8+ T cell Adaptive vaccines are already in clinical trials Abingdon, Oxon, UK, 17th May 2022 – Emergex Vaccines Holding Limited (‘Emergex’, or the ‘Company’), a clinical stage biotechnology company addressing major global infectious diseases through the development of fully synthetic CD8+ T cell Adaptive Vaccines, today announced that its […]
Emergex Provides an Update on First-in-Human Studies of Its Novel Dengue Fever and Coronavirus T cell Adaptive Vaccines
– Both studies fully recruited, with data from the Dengue Fever study anticipated in the summer – Preclinical data for Emergex’s Coronavirus vaccine candidate suggests that it could provide heterologous immunity to viruses from the same family Abingdon, Oxon, UK, 18 April 2022 – Emergex Vaccines Holding Limited (‘Emergex’, or the ‘Company’), a clinical stage […]
Emergex Advances Vaccine Candidate for Tularemia, Highlighting the Potential of T cell Priming Vaccines in National Preparedness Initiatives
· Emergex’s CD8+ T cell Adaptive Vaccine platform will now be used to generate a tularemia vaccine candidate that provides a cytotoxic (killing of infected cells) CD8+ T cell response and offers a means for rapid development suitable for deployment as a medical countermeasure. · Emergex’s ongoing Phase I clinical trials on vaccine candidates for […]
Emergex Signs Agreement with ATCC to Advance Studies of its Yellow Fever Booster Vaccine Candidate
Abingdon, Oxon, UK, 7 April 2022 – Emergex Vaccines Holding Limited (‘Emergex’, or the ‘Company’), a company addressing major global infectious disease threats through the development of fully synthetic CD8+ T-Cell Adaptive Vaccines, today announces that it has entered into an agreement with ATCC to progress preclinical development of its Yellow Fever booster vaccine program. […]
Emergex Awarded £490,525 UK Aid Grant by the Department of Health and Social Care to Advance Synthetic T cell Vaccine Candidate for Chikungunya Virus
Abingdon, Oxon, UK, 22 February 2022 – Emergex Vaccines Holding Limited (‘Emergex’, or ‘the Company’), a company tackling major global infectious disease threats through the development of 100% synthetic Priming T cell Adaptive Vaccines, today announces that it has been awarded a £490,525 grant by the UK government’s Department of Health and Social Care (‘DHSC’) […]
Emergex confirms its next generation T-Cell Priming COVID-19 vaccine candidate has the potential to be effective against all currently sequenced viral mutations
Emergex confirms that the viral peptides in its COVID-19 vaccine candidate are present in the following sequenced variants, including B.1.1.7(Alpha, UK), B.1.1.28 (Gamma, Brazil) B.1.351 (Beta, South Africa), B.1.429 (South Carolina) B.1.617.2 (Delta, India), B.1.1.529 (Omicron, multiple countries) – meaning that no impact on the efficacy of the vaccine is anticipated Emergex’s COVID-19 vaccine uses […]
Emergex announces approval to initiate Phase I clinical trial of its next generation COVID-19 vaccine candidate
Synthetic vaccine designed to prime T-Cells to rapidly remove viral-infected cells from the body after infection May offer broad immunity against SARS-CoV-1 and all SARS-CoV-2 variants and provide long-lasting immunity that does not require seasonal booster vaccines Abingdon, Oxon, UK, 15 November 2021 – Emergex Vaccines Holding Limited (‘Emergex’, or ‘the Company’), a company tackling […]
Next-generation COVID-19 vaccines – looking beyond spike protein and SARS-CoV-1 variants
The response to COVID-19 – a success story in vaccine development The accelerated development of vaccines against COVID-19 and their deployment in mass vaccination programmes has been a major public health achievement. The landscape of vaccine development has undergone rapid change in the global response to the pandemic, with the utilization of novel platforms to […]
Nature paper provides further evidence of the benefits of eliciting a T-Cell response for COVID-19
Abingdon, Oxon, UK, 11 November 2021 – Emergex Vaccines Holding Limited (‘Emergex’, or ‘the Company’), a company tackling major global infectious disease threats through the development of 100% synthetic T Cell priming vaccines was pleased to read an interesting Nature paper published online yesterday, highlighting the role of T-Cells in some COVID-19 patients, providing rapid […]
Can One Vaccine Provide Immune Protection Against Multiple Pathogens?
Can One Vaccine Provide Immune Protection Against Multiple Pathogens? The idea of one vaccine offering a wide range of protection against multiple pathogens or strains is an attractive concept – it would reduce the demands on healthcare systems to deliver vaccination programmes, provide improved uptake of vaccines and reduce the burden for patients who may […]
T-cell priming vaccines offer the potential to provide faster, broader and longer lasting immunity to reduce serious illness associated with infectious diseases such as COVID-19. Here’s why…
T-cell priming vaccines offer the potential to provide faster, broader and longer lasting immunity to reduce serious illness associated with infectious diseases such as COVID-19. Here’s why… The human immune system has evolved over millennia and includes a multitude of different immune effector cells, antibodies and signalling molecules. As our knowledge of this complex system […]
Emergex Receives Regulatory Approval for a Phase I Clinical Trial in Dengue of a T-Cell Priming Vaccine
Swiss regulatory authorities, including the Swiss Agency for Therapeutic Products (Swissmedic) have granted approval for a Phase I clinical trial of Emergex’s Dengue vaccine candidate The Phase I clinical trial will evaluate the safety and look for markers of T-Cell immune response in healthy volunteers Abingdon, Oxon, UK, 30 June 2021 – Emergex Vaccines Holding […]
Emergex Appoints Dr. Anthony Sedgwick as Non-Executive Director
Abingdon, Oxon, UK, 17 June 2021 – Emergex Vaccines Holding Limited (‘Emergex’, or ‘the Company’), a company tackling major global infectious disease threats through the development of synthetic ‘set point’ vaccines which prime the T-Cell immune response, is pleased to announce that Dr. Anthony Sedgwick has been appointed to the Company’s Board as a Non-Executive […]
Emergex Strengthens Senior Management Team
Appointments of Mr Robin Cohen as Business Development Director and Ms Susi Osborne as Manufacturing Director Abingdon, Oxon, UK, 23 February 2021 – Emergex Vaccines Holding Limited (‘Emergex’, or ‘the Company’), a company tackling major global infectious disease threats through the development of synthetic ‘set point’ vaccines which prime the T-Cell immune response, today announces […]
Emergex Notes U.S. Government Reports Highlighting the Importance of T-Cell Immunity in Controlling Viral Infections
Emergex Notes U.S. Government Reports Highlighting the Importance of T-Cell Immunity in Controlling Viral Infections U.S. federal appropriations reports encourage support for T-Cell vaccine approaches for pandemic influenza during the 2021 fiscal year Abingdon, Oxon, UK, 28 January 2021 – Emergex Vaccines Holding Limited (‘Emergex’, or ‘the Company’), a company tackling major global infectious disease […]
Emergex Vaccines signs Collaboration Agreement with Brazil’s Bio-Manguinhos/Fiocruz for the Development of a COVID-19 Vaccine
Bio-Manguinhos, is a world leader in vaccine development and manufacturing and one of the productive units of Fiocruz, one of the world’s most respected public health research institutions Abingdon, Oxon, UK, 5 January 2021 – Emergex Vaccines Holding Limited (‘Emergex’, or ‘the Company’), a company tackling major global infectious disease threats through the development […]
Emergex Vaccines Raises US$11 million to Advance Pipeline of Synthetic T-Cell Vaccines for Infectious Diseases
Investor support further endorsement of vaccine development strategy Novel approach to vaccine development could address urgent global need for safe, effective vaccines that can be rapidly developed and deployed Abingdon, Oxon, UK, 18 November 2020 – Emergex Vaccines Holding Limited (‘Emergex’), a company tackling major global infectious disease threats through the development of synthetic ‘set […]
Emergex Vaccines and George Mason University Identify T-Cell Epitopes Presented by SARS-Cov-2 Infected Cells
First detailed, empirical analysis of Class 1 epitopes presented by SARS-Cov-2 infected cells which define the T-Cell repertoire necessary for cytotoxic T-Cell function MHC expression library provides an accurate basis for COVID-19 T-Cell vaccine and related diagnostics development Doylestown PA, USA and Abingdon, Oxon, UK, 15 September 2020– Emergex Vaccines Holding Limited (‘Emergex’), a company […]
Emergex Vaccines forms US subsidiary (Emergex USA) by acquisition of laboratories, technology and assets of US-based T cell specialist biotech ImmProNano
Acquisition brings critical technical pre-clinical vaccine development capabilities in-house and establishes US based Emergex subsidiary Emergex uniquely develops novel 100% synthetic ‘set-point’ T cell priming vaccines to address some of the world’s most pathogenic infectious diseases Current COVID-19 pandemic and ongoing threat of pandemic flu demonstrate urgent global need for safe, effective vaccines which can […]
Emergex and Bio-Manguinhos/Fiocruz Elucidate T Cell Epitopes Produced by Commercial Yellow Fever Vaccine
First identification of epitopes which shape CD8 T cell response to commercial live attenuated vaccine has implications across RNA virus vaccine development Vaccine primes immune system against T cell epitopes that would be minor or subdominant in a natural infection and are derived from internal proteins Abingdon, UK and Rio de Janeiro, Brazil, 19 August […]
Emergex Signs Agreement with George Mason University for Highly Pathogenic RNA Virus Studies
Emergex Vaccines and George Mason University’s (Mason) National Center for Biodefense and Infectious Diseases (NCBID) enter into an agreement relating to the development of CD8+ priming RNA virus vaccines In particular, NCBID researchers will partner to provide additional expertise, resources, and vital samples to complement Emergex’s existing vaccine programs, including for SARS-CoV-2 Abingdon, UK, 22 […]
Publication of Coronavirus White Papers
Emergex publishes three White Papers highlighting the case for developing set-point vaccines to create a universal coronavirus vaccine
Emergex Raises More Than US$11 million in a Series A Round to Progress its Pipeline of Set-point Vaccines for Infectious Diseases
Emergex develops set-point vaccines to prevent some of the world’s most immediate and virulent diseases such as Zika, Dengue Fever, Ebola and pandemic Flu Vickers Venture Partners led the fundraising and Dr Finian Tan, Chairman of Vickers Venture Partners joins Emergex’s Board of Directors Capital supports pipeline developments, including progressing its first-in-man Flavivirus (Dengue) vaccine […]
Emergex Completes First Step in the Development of a Vaccine Candidate Against Intracellular Bacterium and Bioterrorist Agent Francisella Tularensis
Emergex today announced it has successfully completed the first step in the development of a candidate vaccine for the Gram-negative intracellular coccobacillus, Francisella tularensis.
Emergex Successfully Completes Preclinical Testing of its Lead Set-Point Vaccine Candidate for Dengue Fever and Other Flaviviruses
Emergex today announced the successful completion of preclinical testing of its lead vaccine candidate for Dengue Fever.
Emergex Signs an R&D Agreement with IMCB to Develop a Vaccine for the Emerging Threat of Hand, Foot & Mouth Disease
Emergex today announced that it has signed an R&D agreement with the Institute of Molecular and Cell Biology (IMCB) in Singapore to develop a fully synthetic vaccine against human viruses that cause Hand, Foot and Mouth Disease (HFMD). Emergex and IMCB will collaborate closely to develop the new vaccine, combining their personnel, specialist knowledge and expertise.
Dr. Athanasios Papadopoulos Joins Emergex as Chief Medical Officer
Emergex today announces the appointment of Athanasios Papadopoulos, MD, as Chief Medical Officer (CMO), effective 1st March 2019. Dr. Papadopoulos will report directly to Emergex’s CEO Professor Thomas Rademacher.
Emergex Secures State-of-the-art R&D Facility and Hires a Chief Scientific Officer to Drive Development of its Vaccines
Emergex Vaccines Holding Limited (‘Emergex’), a biotechnology company pioneering a novel approach to the development of vaccines for infectious diseases, today announces that it has successfully secured a state-of-the-art-research and development (R&D) facility at Milton Park, Oxfordshire.
Emergex Demonstrates Excellent Safety Profile for Gold Nanoparticle Used in its Vaccine Platform
Emergex Vaccines Holding Limited (‘Emergex’), a biotechnology company pioneering a new approach to synthetic vaccine development in the field of infectious diseases, today announces the successful completion of preclinical toxicology testing on the gold nanoparticle carrier system that forms the fundamental basis for Emergex’s entire infectious disease vaccine platform.
Emergex Enters into MoU with Brazil’s Fiocruz to Develop Novel Vaccines Against Viral Diseases
Emergex Vaccines Holding Limited (‘Emergex’), a biotechnology company pioneering a new approach to synthetic vaccine development in the field of infectious diseases, today announces that it has signed a Memorandum of Understanding (MoU) with Brazil-based Oswaldo Cruz Foundation ‘Fiocruz’ for the development of viral vaccines. The MoU initially covers the development of a vaccine that universally targets diseases within the flavivirus family such as Dengue Fever, Zika and Yellow Fever but could be expanded to include the development of vaccines to target other viral families that are endemic to the region.
Emergex Appoints US Federal Government Experts The Conafay Group
Emergex Vaccines Holding Limited (‘Emergex’), a biotechnology company pioneering a new approach to vaccine development in the field of infectious diseases, today announces that it has appointed The Conafay Group, US Federal Government experts, to advise on the US healthcare landscape and policy and to provide introductions to help establish new business contacts.
Emergex Files a Patent in the USA for its Novel Pandemic Flu Vaccine
Emergex Vaccines Holding Limited (‘Emergex’), a biotechnology company pioneering a new approach to enable synthetic vaccine development in the field of infectious diseases, today announces that it has filed a patent in the USA for its novel pandemic flu vaccine.
Emergex Awarded Innovate UK Grant to Progress its Universal and Pandemic Flu Vaccine
Emergex Vaccines Holding Limited (‘Emergex’), a biotechnology company pioneering a new approach to vaccine development in the field of infectious diseases, today announces that Innovate UK, the UK’s innovation agency, has awarded the company a grant of £979,318 to progress its universal flu vaccine programme through preclinical development.
Sir David King Joins Emergex’s Board of Directors
Emergex Vaccines Holding Limited (‘Emergex’), a biotechnology company pioneering a new approach to vaccine development in the field of infectious diseases, today announces that Sir David King has joined Emergex’s Board as a Non-Executive Director.
Emergex Builds its Finance Team with Two New Recruits
Emergex Vaccines Holding Limited (‘Emergex’), a biotechnology company pioneering a new approach to vaccine development in the field of infectious diseases, today announces that it has built its Finance team and strengthening its operational capabilities.
Emergex Progresses its Synthetic Vaccine Development Pipeline
Emergex Vaccines Holding Limited (“Emergex”), a private biotechnology company pioneering a new approach to vaccine development in the field of infectious diseases, today provides an update on its vaccine development pipeline and business.
Emergex Vaccines Awarded SBRI Contract by Innovate UK
Emergex Vaccines Holding Limited (“Emergex”), a biotechnology company pioneering a new approach to T-cell vaccine development in the field of infectious diseases, today announced that they have been awarded a £499,825 SBRI contract with the Department of Health/Technology Strategy Board, facilitated by Innovate UK, the UK’s Innovation Agency. The ‘Vaccines for Global Development – Preclinical’ grant proceeds will be used to advance the Zika and multivalent filovirus (Ebola and Marburg) vaccine programmes.
Emergex Vaccines Approved as Member of the Social Stock Exchange
Emergex Vaccines Holding Limited (“Emergex”), a biotechnology company pioneering a new approach to T-cell vaccine development in the field of infectious diseases, today announces that they have been approved as a member of the Social Stock Exchange, society’s market for impact investing. This follows the ratification of Emergex’s impact report by the Social Stock Exchange’s independent Admissions Panel.
Emergex Vaccines Provides an Update on Agreement with Midatech Pharma
Emergex Vaccines Holding Limited (“Emergex”), a biotechnology company pioneering a new approach to T-cell vaccine development in the field of infectious diseases, today announced that it has paid an upfront technology access fee and option payment of £450,000 to Midatech Pharma (AIM: MTPH, NASDAQ: MTP), under the terms of the contract. This follows the licence granted to Emergex from Midatech Pharma, which was announced in January this year.